Lonza to acquire Roche biologics manufacturing site for $1.2bn

21 Mar 2024
www.pharmaceutical-technology.com
Acquisition
Lonza to acquire Roche biologics manufacturing site for $1.2bn
Preview
Source: Pharmaceutical Technology
Lonza intends to make an investment of $562.2m to renovate the Vacaville site. Credit: Taljat David / Shutterstock.com.
Swiss contract manufacturer Lonza has agreed to acquire the Genentech large-scale biologics manufacturing facility in Vacaville, California, US, from Roche in a $1.2bn deal.
The strategic move is set to bolster Lonza’s capacity for large-scale biologics manufacturing.
The site has a bioreactor capacity of 330,000 litres – one of the world’s largest by volume.
The acquisition aims to meet the rising demand for commercial mammalian contract manufacturing, catering to customers with products already in the market and those with molecules advancing towards commercialisation within Lonza’s network.
750 Genentech employees at the site will become part of Lonza.
See Also:
Delivery and manufacturing hurdles remain in the cell and gene therapy
Lonza to acquire Roche biologics manufacturing site for $1.2bn
Preview
Source: Pharmaceutical Technology
Acquired (Autoimmune) Hemolytic Anemia drugs in development, 2023
Lonza to acquire Roche biologics manufacturing site for $1.2bn
Preview
Source: Pharmaceutical Technology
The deal will provide Lonza’s customers with rapid access to substantial new capacity in the US. It will establish a significant West Coast commercial manufacturing presence for Lonza, complementing its East Coast site in Portsmouth and its international network spanning Europe and Asia.
Lonza intends to invest SFr500m ($562.2m) to renovate the Vacaville site and bolster its capabilities to produce mammalian biologics therapies.
Roche-manufactured products at the facility will be distributed by Lonza, with committed volumes over the medium term, gradually transitioning to serve other customers.
The deal will conclude in the second half of 2024.
The Vacaville facility will be merged into Lonza’s biologics division, joining its network of mammalian manufacturing units in Visp, Slough, Singapore, Portsmouth and Porriño.
Lonza Biologics president Jean-Christophe Hyvert stated: “The Vacaville site is a highly valuable strategic acquisition that will make capacity immediately available for our customers and unlock future growth for our biologics division.
“It will support us in providing a commercialisation path to existing customers and incremental large-scale commercial capacity to our partners. We have deep and long-standing industrial expertise in delivering commercial scale manufacturing services for our customers’ therapies.”
In June 2023, Lonza boosted its antibody-drug conjugates offering with the acquisition of Dutch company Synaffix for $172m.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.